Efficacy and safety of omalizumab therapy in urticaria vasculitis

Urticarial vasculitis (UV) is a small-vessel leukocytoclastic vasculitis characterized by different clinical manifestations ranging from long-lasting urticarial lesions to severe and potentially life-threatening multi-organ involvement. Omalizumab (OMA), anti-IgE recombinant humanized IgG1 monoclona...

Descripción completa

Detalles Bibliográficos
Autores principales: Petrelli, Fiorella, Giannini, Daiana, Bilia, Silvia, Del Corso, Isabella, Rocchi, Valeria, Migliorini, Paola, Puxeddu, Ilaria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Allergy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353047/
https://www.ncbi.nlm.nih.gov/pubmed/35935020
http://dx.doi.org/10.3389/falgy.2022.952079
_version_ 1784762788245143552
author Petrelli, Fiorella
Giannini, Daiana
Bilia, Silvia
Del Corso, Isabella
Rocchi, Valeria
Migliorini, Paola
Puxeddu, Ilaria
author_facet Petrelli, Fiorella
Giannini, Daiana
Bilia, Silvia
Del Corso, Isabella
Rocchi, Valeria
Migliorini, Paola
Puxeddu, Ilaria
author_sort Petrelli, Fiorella
collection PubMed
description Urticarial vasculitis (UV) is a small-vessel leukocytoclastic vasculitis characterized by different clinical manifestations ranging from long-lasting urticarial lesions to severe and potentially life-threatening multi-organ involvement. Omalizumab (OMA), anti-IgE recombinant humanized IgG1 monoclonal antibody, has been successfully used to treat few cases of severe and/or refractory UV. In this study we report our experience on 6 patients with refractory normocomplementemic UV successfully treated with anti-IgE therapy (OMA), suggesting that this biological therapy may be a safe and effective therapeutic option in UV.
format Online
Article
Text
id pubmed-9353047
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93530472022-08-06 Efficacy and safety of omalizumab therapy in urticaria vasculitis Petrelli, Fiorella Giannini, Daiana Bilia, Silvia Del Corso, Isabella Rocchi, Valeria Migliorini, Paola Puxeddu, Ilaria Front Allergy Allergy Urticarial vasculitis (UV) is a small-vessel leukocytoclastic vasculitis characterized by different clinical manifestations ranging from long-lasting urticarial lesions to severe and potentially life-threatening multi-organ involvement. Omalizumab (OMA), anti-IgE recombinant humanized IgG1 monoclonal antibody, has been successfully used to treat few cases of severe and/or refractory UV. In this study we report our experience on 6 patients with refractory normocomplementemic UV successfully treated with anti-IgE therapy (OMA), suggesting that this biological therapy may be a safe and effective therapeutic option in UV. Frontiers Media S.A. 2022-07-22 /pmc/articles/PMC9353047/ /pubmed/35935020 http://dx.doi.org/10.3389/falgy.2022.952079 Text en Copyright © 2022 Petrelli, Giannini, Bilia, Del Corso, Rocchi, Migliorini and Puxeddu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Allergy
Petrelli, Fiorella
Giannini, Daiana
Bilia, Silvia
Del Corso, Isabella
Rocchi, Valeria
Migliorini, Paola
Puxeddu, Ilaria
Efficacy and safety of omalizumab therapy in urticaria vasculitis
title Efficacy and safety of omalizumab therapy in urticaria vasculitis
title_full Efficacy and safety of omalizumab therapy in urticaria vasculitis
title_fullStr Efficacy and safety of omalizumab therapy in urticaria vasculitis
title_full_unstemmed Efficacy and safety of omalizumab therapy in urticaria vasculitis
title_short Efficacy and safety of omalizumab therapy in urticaria vasculitis
title_sort efficacy and safety of omalizumab therapy in urticaria vasculitis
topic Allergy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353047/
https://www.ncbi.nlm.nih.gov/pubmed/35935020
http://dx.doi.org/10.3389/falgy.2022.952079
work_keys_str_mv AT petrellifiorella efficacyandsafetyofomalizumabtherapyinurticariavasculitis
AT gianninidaiana efficacyandsafetyofomalizumabtherapyinurticariavasculitis
AT biliasilvia efficacyandsafetyofomalizumabtherapyinurticariavasculitis
AT delcorsoisabella efficacyandsafetyofomalizumabtherapyinurticariavasculitis
AT rocchivaleria efficacyandsafetyofomalizumabtherapyinurticariavasculitis
AT migliorinipaola efficacyandsafetyofomalizumabtherapyinurticariavasculitis
AT puxedduilaria efficacyandsafetyofomalizumabtherapyinurticariavasculitis

Ejemplares similares